Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542452 | 1.00 | CHRM1 (0.46) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL1542861 | 1.00 | CHRM1 (0.46) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5710592 | 0.85 | CHRNA7 (0.40) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5395242 | 0.84 | CHRNA7 (0.50) | CHRM1CHRM2CHRNA7 | |
| SCHEMBL417280 | 0.82 | CHRM1 (0.39) | CHRM1CHRM2CHRNA7HMOX1 | |
| SCHEMBL3844303 | 0.80 | CHRNA7 (0.48) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL999498 | 0.80 | CHRNA7 (0.48) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL999496 | 0.80 | CHRNA7 (0.48) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL1542353 | 0.80 | CHRM1 (0.49) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL1542354 | 0.80 | CHRM1 (0.49) | CHRM1CHRM2CHRNA7CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190083474-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2019-03-21 | — | — | US | disclosed |
| US-20180078536-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2018-03-22 | — | — | US | disclosed |
| US-9849117-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2017-12-26 | — | — | US | disclosed |
| US-20170112814-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-9567343-B2 | Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| US-20150183794-A1 | AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-9012451-B2 | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists | NOVARTIS AG (CH) | 2015-04-21 | — | — | US | disclosed |
| US-20120220599-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-8236803-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | JI JIANGUO | 2007-11-29 | — | — | US | disclosed |
| US-20070249617-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | disclosed |
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060167002-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | FEUERBACH DOMINIK | 2006-07-27 | — | — | US | disclosed |
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137203-A1 | 3-quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| EP-1537104-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONIST | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022556-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONIST | NOVARTIS AG (CH) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | CHRNA7, CHRNA9, CHRNA1 | CHRM1 36/4885CHRM2 35/4885CHRNA7 1/4885 |
| US-20150183794-A1 | AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRM1 19/4885CHRM2 21/4885CHRNA7 1/4885 |
| US-20170112814-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRM1 18/4885CHRM2 21/4885CHRNA7 1/4885 |
| US-20070249617-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | CHRNA7, CHRNA1, CHRNE | CHRM1 18/4885CHRM2 21/4885CHRNA7 1/4885 |
| US-20180078536-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRM1 18/4885CHRM2 21/4885CHRNA7 1/4885 |
| US-20060167002-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | CHRNA7, CHRNA1, CHRNE | CHRM1 19/4885CHRM2 21/4885CHRNA7 1/4885 |
| US-20120220599-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRM1 18/4885CHRM2 21/4885CHRNA7 1/4885 |
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA1, CHRNA2, CHRM2 | CHRM1 5/4885CHRM2 3/4885CHRNA7 8/4885 |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | CHRNA7, CHRNA9, CHRNA1 | CHRM1 36/4885CHRM2 35/4885CHRNA7 1/4885 |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA3, CHRNA1, CHRM3 | CHRM1 8/4885CHRM2 6/4885CHRNA7 11/4885 |
| US-20050137203-A1 | 3-quinuclidinyl amino-substituted biaryl derivatives | CHRNA9, CHRNA7, CHRNA1 | CHRM1 37/4885CHRM2 34/4885CHRNA7 2/4885 |
| US-20190083474-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRM1 18/4885CHRM2 21/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.